Pfizer (PFE) Inc. Equity Report (Q1FY22)

Highlights of the report

Pfizer forecasts $32bn in revenue for COVID-19 vaccine Comirnaty, and $22bn for oral COVID-19 treatment Paxlovid, in 2022. Pfizer Inc. said that surging sales of its COVID-19 treatment and continued demand for its shots will likely boost the company’s revenue to around $100bn in FY22.

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.


CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).


Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands etc…

PFE revenue increased $11.1bn, or 77%, to $25.7bn in Q1FY22 from $14.5bn in Q1FY21, reflecting an
operational increase of $11.9bn, or 82%, as well as an unfavorable impact of foreign exchange of $778mn, or
5%. Excluding direct sales and alliance revenues of Comirnaty and sales of Paxlovid, revenues increased 2%
operationally, reflecting strong growth in the Prevnar family in the U.S., Eliquis, Vyndaqel/Vyndamax, Oncology
biosimilars and Ibrance internationally, partially offset by declines in Chantix/Champix, Xeljanz and Ibrance in
the U.S

The YTD stock performance of the company shows a decline of 7.76%. The stock of the company remained
volatile over the period and is currently trading at $53.04.



– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

Report details

Pfizer (PFE) Inc. Equity Report (Q1FY22)



Company Reports

Sector Reports